White matter integrity as a predictor of response to treatment in first episode psychosis

Brain

Volumn 137, Issue 1, 2014, Pages 172-182

  Reis Marques, Tiago ^a   Taylor, Heather ^a   Chaddock, Chris ^a   Dell'Acqua, Flavio ^a   Handley, Rowena ^a   Reinders, A A T Simone ^a   Mondelli, Valeria ^a   Bonaccorso, Stefania ^a   Diforti, Marta ^a   Simmons, Andrew ^a   David, Anthony S ^a   Murray, Robin M ^a   Pariante, Carmine M ^a   Kapur, Shitij ^a   Dazzan, Paola ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antipsychotic drugs; diffusion tensor imaging; psychosis; schizophrenia; white matter

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CAPSULA INTERNA; CEREBELLAR PEDUNCLE; CEREBRAL PEDUNCLE; CONTROLLED STUDY; CORONA RADIATA (BRAIN); CORPUS CALLOSUM; DIFFUSION TENSOR IMAGING; DRUG EXPOSURE; EXTERNAL CAPSULE; FEMALE; FRACTIONAL ANISOTROPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAL LEMNISCUS; NEUROIMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; STRIA TERMINALIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNCINATE FASCICULUS; WHITE MATTER;

ANTIPSYCHOTIC DRUGS; DIFFUSION TENSOR IMAGING; PSYCHOSIS; SCHIZOPHRENIA; WHITE MATTER;

ADULT; ANISOTROPY; ANTIPSYCHOTIC AGENTS; BRAIN; DIFFUSION TENSOR IMAGING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERNATIONAL CLASSIFICATION OF DISEASES; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; PREDICTIVE VALUE OF TESTS; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 84892688701     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt310     Document Type: Article

References (47)

1. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus [Review]. Am J Psychiatry 2005; 162: 441-9.
2. Annett M. A classification of hand preference by association analysis. Br J Psychol 1970; 61: 303-21.
3. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 2008; 34: 1163-71.
4. Atkins M, Burgess A, Bottomley C, Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research implications. Psychiatr Bull 1997; 21: 224-6.
5. Bartzokis G, Lu PH, Stewart SB, Oluwadara B, Lucas AJ, Pantages J, et al. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr Res 2009; 113: 322-31.
6. Bartzokis G. Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology 2012; 62: 2137-53.
7. Bebbington PE, Nayani T. The psychosis screening questionnaire. Int J Methods Psychiatr Res 1995; 5: 11-20.
8. Bodnar M, Achim AM, Malla AK, Joober R, Benoit A, Lepage M. Functional magnetic resonance imaging correlates of memory encoding in relation to achieving remission in first episode schizophrenia. Br J Psychiatry 2012; 200: 300-7.
9. Borgwardt S, Fusar-Poli P. Third-generation neuroimaging in early schizophrenia: translating research evidence into clinical utility. Br J Psychiatry 2012; 200: 270-2.
10. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al. Effectiveness of antipsychotics in first episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009; 115: 97-103.
11. Carletti F, Woolley JB, Bhattacharyya S, Perez-Iglesias R, Fusar Poli P, Valmaggia L, et al. Alterations in white matter evident before the onset of psychosis. Schizophr Bull 2012; 38: 1170-9.
12. Catani M, Howard RJ, Pajevic S, Jones DK. Virtual in vivo interactive dissection of white matter fasciculi in the human brain. Neuroimage 2002; 17: 77-94.
13. Catani M, Thiebaut de Schotten M. A diffusion tensor imaging tractography atlas for virtual in vivo dissections. Cortex 2008; 44: 1105-32.
14. Chandran P, Upadhyay J, Markosyan S, Lisowski A, Buck W, Chin CL, et al. Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice. Neuroscience 2012; 202: 446-53.
15. Cheung V, Cheung C, McAlonan GM, Deng Y, Wong JG, Yip L, et al. A diffusion tensor imaging study of structural dysconnectivity in nevermedicated, first episode schizophrenia. Psychol Med 2008; 38: 877-85.
16. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003; 160: 2063-5.
17. Garner B, Berger GE, Nicolo JP, Mackinnon A, Wood SJ, Pariante CM, et al. Pituitary volume and early treatment response in drug-na?̈ve first episode psychosis patients. Schizophr Res 2009; 113: 65-71.
18. Garver DL, Holcomb JA, Christensen JD. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int J Neuropsychopharmacol 2008; 11: 49-61.
19. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first episode schizophrenia. Arch Gen Psychiatry 2011; 68: 128-37.
20. Jablensky A, Sartorius N, Ernberg G, Anker A, Cooper JE, Day R, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992; 20: 1-97.
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
22. Kubicki M, McCarley RW, Shenton ME. Evidence for white matter abnormalities in schizophrenia. Curr Opin Psychiatry 2005; 18: 121-34.
23. Luck D, Buchy L, Czechowska Y, Bodnar M, Pike GB, Campbell JS, et al. Fronto-temporal disconnectivity and clinical short-term outcome in first episode psychosis: a DTI-tractography study. J Psychiatr Res 2011; 45: 369-77.
24. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991; 48: 764-70.
25. McGuire PK, Frith CD. Disordered functional connectivity in schizophrenia. Psychol Med 1996; 26: 663-7.
26. Mitelman SA, Newmark RE, Torosjan Y, Chu KW, Brickman AM, Haznedar MM, et al. White matter fractional anisotropy and outcome in schizophrenia. Schizophr Res 2006; 87: 138-59.
27. Mitelman SA, Canfield EL, Newmark RE, Brickman AM, Torosjan Y, Chu KW, et al. Longitudinal assessment of gray and white matter in chronic schizophrenia: a combined diffusion-tensor and structural magnetic resonance imaging study open. Neuroimag J 2009; 3: 31-47.
28. Mondelli V, Dazzan P, Hepgul N, Di Forti M, Aas M, D'Albenzio A, et al. Abnormal cortisol levels during the day and cortisol awakening response in first episode psychosis: the role of stress and of antipsychotic treatment. Schizophr Res 2010; 116: 234-42.
29. Mori T, Ohnishi T, Hashimoto R, Nemoto K, Moriguchi Y, Noguchi H, et al. Progressive changes of white matter integrity in schizophrenia revealed by diffusion tensor imaging. Psychiatry Res 2007; 154: 133-45.
30. Mourao-Miranda J, Reinders AA, Rocha-Rego V, Lappin J, Rondina J, Morgan C, et al. Individualized prediction of illness course at the first psychotic episode: a support vector machine MRI study. Psychol Med 2012; 42: 1037-47.
31. Palaniyappan L, Reis Marques T, Taylor H, Handley R, Mondelli V, Bonaccorso S, et al. Cortical folding defects as markers of poor treatment response in first episode psychosis. JAMA Psychiatry 2013; 70: 1031-40.
32. Pé rez-Iglesias R, Tordesillas-Gutié rrez D, Barker GJ, McGuire PK, Roiz-Santiañ ez R, Mata I, et al.White matter defects in first episode psychosis patients: a voxelwise analysis of diffusion tensor imaging. Neuroimage, 2010, 49, 199-204.
33. Simmons A, Moore E, Williams SC. Quality control for functional magnetic resonance imaging using automated data analysis and Shewhart charting. Magn Reson Med 1999; 41: 1274-8.
34. Skelly LR, Calhoun V, Meda SA, Kim J, Mathalon DH, Pearlson GD. Diffusion tensor imaging in schizophrenia: relationship to symptoms. Schizophr Res 2008; 98: 157-62.
35. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002; 17: 143-55.
36. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL [Review]. Neuroimage 2004; 23 (Suppl 1): S208-19.
37. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006; 31: 1487-505.
38. Song SK, Sun SW, Ramsbottom MJ, Chang C, Russell J, Cross AH. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 2002; 17: 1429-36.
39. Song SK, Sun SW, Ju WK, Lin SJ, Cross AH, Neufeld AH. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage 2003; 20: 1714-22.
40. Taylor D, Paton C, Kerwin RW. The Maudsley Prescribing Guidelines. 9th edn. London: Informa Health Care; 2007.
41. Van Veelen NM, Vink M, Ramsey NF, van Buuren M, Hoogendam JM, Kahn RS. Prefrontal lobe dysfunction predicts treatment response in medication-naive first episode schizophrenia. Schizophr Res 2011; 129: 156-62.
42. Wang Q, Cheung C, Deng W, Li M, Huang C, Ma X, et al. Whitematter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment. Psychol Med 2013; 43: 2301-9.
43. Wechsler D. WAIS-III administration and scoring manual. 3rd edn. San Antonio, TX: The Psychological Corporation; 1997.
44. White T, Magnotta VA, Bockholt HJ, Williams S, Wallace S, Ehrlich S, et al. Global white matter abnormalities in schizophrenia: a multisite diffusion tensor imaging study. Schizophr Bull 2011; 37: 222-32.
45. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics [Review]. J Clin Psychiatry 2003; 64: 663-7.
46. Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 2008; 13: 697-708.
47. Zhang Y, Zhang H, Wang L, Jiang W, Xu H, Xiao L, et al. Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination. Schizophr Res 2012; 138: 8-17.